Roivant Sciences Ltd. ROIV
ROIV among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
ROIV and 9 peers, year by year
The 9 Health care companies closest to ROIV in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences Ltd. | FY2026 | $8.3M | −71.6% | n/m | n/m | n/m | −6.6% | - |
| IDYA IDEAYA Biosciences, Inc. | FY2025 | $218.7M | n/m | −72.8% | −52.0% | −33.6% | −11.1% | - |
| OCUL Ocular Therapeutix, Inc | FY2025 | $52.0M | −18.5% | −519.8% | −511.9% | −417.5% | −40.6% | 0.11 |
| CRSP CRISPR Therapeutics AG | FY2025 | $3.5M | −90.6% | n/m | n/m | n/m | −30.3% | 0.00 |
| RXRX Recursion Pharmaceuticals, Inc. | FY2025 | $74.7M | +26.9% | −867.9% | −863.4% | −506.5% | −57.0% | 0.02 |
| CGON CG Oncology, Inc. | FY2025 | $4.0M | +255% | n/m | n/m | n/m | −21.4% | 0.00 |
| SRRK Scholar Rock Holding Corp | FY2025 | $0 | - | - | - | - | −154.0% | 0.41 |
| KYMR Kymera Therapeutics, Inc. | FY2025 | $39.2M | −16.7% | −891.1% | −794.0% | −597.6% | −19.7% | - |
| CYTK Cytokinetics Inc | FY2025 | $88.0M | +377% | −695.4% | −891.6% | −607.5% | n/m | n/m |
| AGIO Agios Pharmaceuticals, Inc. | FY2025 | $54.0M | +48.0% | −873.9% | −764.0% | −698.3% | −34.6% | - |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2021 to FY2026 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2021 to FY2026
Revenue as reported in the 10-K.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M |
| IDYA Dec | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M | - |
| OCUL Dec | $43.5M | $51.5M | $58.4M | $63.7M | $52.0M | - |
| CRSP Dec | $915.0M | $1.2M | $371.2M | $37.3M | $3.5M | - |
| RXRX Dec | $10.2M | $39.8M | $44.6M | $58.8M | $74.7M | - |
| CGON Dec | - | - | $204K | $1.1M | $4.0M | - |
| SRRK Dec | $18.8M | $33.2M | - | - | $0 | - |
| KYMR Dec | $72.8M | $46.8M | $78.6M | $47.1M | $39.2M | - |
| CYTK Dec | $70.4M | $94.6M | $7.5M | $18.5M | $88.0M | - |
| AGIO Dec | $0 | $14.2M | $26.8M | $36.5M | $54.0M | - |
| Peer median | $35.7M | $43.3M | $35.7M | $36.9M | $52.0M | - |
Sales growth, FY2021 to FY2026
Revenue against the fiscal year before.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | - | +132% | +10.8% | +3.8% | −11.2% | −71.6% |
| IDYA Dec | +43.0% | +82.3% | −54.1% | −70.1% | n/m | - |
| OCUL Dec | +150% | +18.3% | +13.5% | +9.0% | −18.5% | - |
| CRSP Dec | n/m | −99.9% | n/m | −89.9% | −90.6% | - |
| RXRX Dec | +157% | +291% | +11.9% | +32.0% | +26.9% | - |
| CGON Dec | - | - | - | +458% | +255% | - |
| SRRK Dec | +22.2% | +76.4% | - | - | - | - |
| KYMR Dec | +114% | −35.7% | +67.8% | −40.1% | −16.7% | - |
| CYTK Dec | +26.2% | +34.3% | −92.0% | +145% | +377% | - |
| AGIO Dec | - | - | +88.4% | +36.1% | +48.0% | - |
| Peer median | +78.5% | +34.3% | +12.7% | +20.5% | +26.9% | - |
Operating margin, FY2021 to FY2026
Operating income / revenue.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | n/m | n/m | n/m | n/m | n/m | n/m |
| IDYA Dec | −179.9% | −122.7% | −574.9% | n/m | −72.8% | - |
| OCUL Dec | −179.3% | −152.7% | −141.0% | −269.6% | −519.8% | - |
| CRSP Dec | 40.8% | n/m | −60.0% | n/m | n/m | - |
| RXRX Dec | n/m | −616.7% | −785.3% | −814.1% | −867.9% | - |
| CGON Dec | - | - | n/m | n/m | n/m | - |
| SRRK Dec | −690.5% | −404.8% | - | - | - | - |
| KYMR Dec | −138.0% | −344.4% | −210.6% | −555.8% | −891.1% | - |
| CYTK Dec | −264.5% | −342.8% | n/m | n/m | −695.4% | - |
| AGIO Dec | - | n/m | n/m | n/m | −873.9% | - |
| Peer median | −179.6% | −343.6% | −210.6% | −555.8% | −781.7% | - |
Net margin, FY2021 to FY2026
Net income / revenue.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | n/m | n/m | n/m | n/m | −592.0% | n/m |
| IDYA Dec | −178.1% | −115.2% | −483.0% | n/m | −52.0% | - |
| OCUL Dec | −15.1% | −138.0% | −138.1% | −303.7% | −511.9% | - |
| CRSP Dec | 41.3% | n/m | −41.4% | −981.5% | n/m | - |
| RXRX Dec | n/m | −601.0% | −736.0% | −788.0% | −863.4% | - |
| CGON Dec | - | - | n/m | n/m | n/m | - |
| SRRK Dec | −700.5% | −405.2% | - | - | - | - |
| KYMR Dec | −137.6% | −330.6% | −187.0% | −475.6% | −794.0% | - |
| CYTK Dec | −305.7% | −411.2% | n/m | n/m | −891.6% | - |
| AGIO Dec | - | n/m | n/m | n/m | −764.0% | - |
| Peer median | −157.8% | −367.9% | −187.0% | −631.8% | −779.0% | - |
Free cash flow, FY2021 to FY2026
Cash from operations minus capital spending.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | −$557.9M | −$695.2M | −$856.1M | −$766.6M | −$844.0M | −$758.6M |
| IDYA Dec | −$58.4M | −$90.6M | −$117.6M | −$251.4M | −$73.5M | - |
| OCUL Dec | −$66.7M | −$63.3M | −$76.3M | −$136.0M | −$216.9M | - |
| CRSP Dec | $457.3M | −$532.9M | −$269.8M | −$144.7M | −$345.9M | - |
| RXRX Dec | −$198.4M | −$120.6M | −$299.7M | −$372.9M | −$378.3M | - |
| CGON Dec | - | - | - | −$78.9M | −$132.5M | - |
| SRRK Dec | −$132.0M | −$133.8M | −$145.3M | −$201.0M | −$300.6M | - |
| KYMR Dec | −$130.5M | −$155.9M | −$137.3M | −$207.3M | −$234.3M | - |
| CYTK Dec | −$191.4M | −$310.9M | −$415.7M | −$399.8M | −$534.8M | - |
| AGIO Dec | −$413.1M | −$314.4M | −$297.1M | −$391.5M | −$377.3M | - |
| Peer median | −$131.3M | −$144.8M | −$207.6M | −$207.3M | −$300.6M | - |
FCF margin, FY2021 to FY2026
Free cash flow / revenue.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | n/m | n/m | n/m | n/m | n/m | n/m |
| IDYA Dec | −209.1% | −177.9% | −502.9% | n/m | −33.6% | - |
| OCUL Dec | −153.4% | −123.0% | −130.6% | −213.4% | −417.5% | - |
| CRSP Dec | 50.0% | n/m | −72.7% | −387.7% | n/m | - |
| RXRX Dec | n/m | −302.6% | −672.4% | −633.7% | −506.5% | - |
| CGON Dec | - | - | - | n/m | n/m | - |
| SRRK Dec | −701.7% | −403.0% | - | - | - | - |
| KYMR Dec | −179.2% | −333.0% | −174.7% | −440.5% | −597.6% | - |
| CYTK Dec | −271.8% | −328.6% | n/m | n/m | −607.5% | - |
| AGIO Dec | - | n/m | n/m | n/m | −698.3% | - |
| Peer median | −194.2% | −315.6% | −174.7% | −414.1% | −552.1% | - |
Return on equity, FY2021 to FY2026
Net income / shareholders' equity at the year end.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | −45.0% | −51.0% | −87.2% | 72.9% | −3.7% | −6.6% |
| IDYA Dec | −16.5% | −16.8% | −18.2% | −25.9% | −11.1% | - |
| OCUL Dec | −7.4% | n/m | −88.6% | −61.4% | −40.6% | - |
| CRSP Dec | 15.7% | −34.7% | −8.2% | −19.0% | −30.3% | - |
| RXRX Dec | −34.3% | −49.3% | −70.8% | −44.8% | −57.0% | - |
| CGON Dec | - | - | n/m | −12.0% | −21.4% | - |
| SRRK Dec | −76.6% | −51.7% | −73.6% | −66.8% | −154.0% | - |
| KYMR Dec | −21.8% | −31.6% | −37.2% | −26.8% | −19.7% | - |
| CYTK Dec | −88.3% | n/m | n/m | n/m | n/m | - |
| AGIO Dec | 124.2% | −21.1% | −43.4% | 43.7% | −34.6% | - |
| Peer median | −19.2% | −33.1% | −43.4% | −26.4% | −32.4% | - |
Debt / equity, FY2021 to FY2026
Total debt / shareholders' equity at the year end.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | 0.09 | 0.13 | 0.32 | 0.07 | - | - |
| IDYA Dec | - | - | - | - | - | - |
| OCUL Dec | 0.28 | 0.71 | 0.72 | 0.22 | 0.11 | - |
| CRSP Dec | - | - | - | - | 0.00 | - |
| RXRX Dec | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | - |
| CGON Dec | - | - | - | 0.00 | 0.00 | - |
| SRRK Dec | 0.31 | 0.20 | 0.23 | 0.14 | 0.41 | - |
| KYMR Dec | - | - | - | - | - | - |
| CYTK Dec | 0.19 | n/m | n/m | n/m | n/m | - |
| AGIO Dec | - | - | - | - | - | - |
| Peer median | 0.24 | 0.20 | 0.23 | 0.08 | 0.02 | - |
EPS (diluted), FY2021 to FY2026
Diluted earnings per share, on today's share count after splits.
| Company | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
| ROIV Mar | −$1.28 | −$1.26 | −$1.42 | $5.23 | −$0.24 | −$0.54 |
| IDYA Dec | −$1.41 | −$1.42 | −$1.96 | −$3.36 | −$1.28 | - |
| OCUL Dec | −$0.98 | −$0.97 | −$1.02 | −$1.22 | −$1.42 | - |
| CRSP Dec | $4.70 | −$8.36 | −$1.94 | −$4.34 | −$6.47 | - |
| RXRX Dec | −$1.49 | −$1.36 | −$1.58 | −$1.69 | −$1.44 | - |
| CGON Dec | - | - | −$15.65 | −$1.41 | −$2.08 | - |
| SRRK Dec | −$3.59 | −$2.26 | −$1.99 | −$2.47 | −$3.29 | - |
| KYMR Dec | −$2.09 | −$2.87 | −$2.52 | −$2.98 | −$3.69 | - |
| CYTK Dec | −$2.80 | −$4.33 | −$5.45 | −$5.26 | −$6.54 | - |
| AGIO Dec | $26.55 | −$4.23 | −$6.33 | $11.64 | −$7.12 | - |
| Peer median | −$1.45 | −$2.56 | −$1.99 | −$2.47 | −$3.29 | - |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out ROIV and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: ROIV's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ROIV/export.csv") into a cell.